Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study

Fig. 1

Rituximab (RTX) non-responders (NR) have higher baseline lymphocyte, T cell, and CD4+lymphocyte counts than responders (R). Lymphocyte (a), CD45+CD3+ (b), CD45+CD19+ (c), and CD45+CD3+CD4+ (d) counts were obtained before treatment with RTX. European League Against Rheumatism (EULAR) response and disease activity score in 28 joints (DAS28) were assessed at week 24 after treatment with RTX. Data are presented as cells/μl. Each dot represents a patient; horizontal bars indicate the mean. Statistical significance was assessed using the Mann-Whitney U test. *P <0.05, ***P <0.001

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us